Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Serina has over 17 years of experience in the biopharmaceutical industry
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Subscribe To Our Newsletter & Stay Updated
